Dunhill Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Dunhill Financial’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52	Hold	3	–	–	﹤0.01%	1508
2026 Q1	$37	Hold	3	–	–	﹤0.01%	1672
2025 Q4	$38	Buy	+3	New	+$34	﹤0.01%	1742

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dunhill Financial's AMRX Position: Q2 2026 in Review

Dunhill Financial held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 3 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #1508.

Dunhill Financial first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Dunhill Financial held 3 shares of Amneal Pharmaceuticals worth $52 as of Q2 2026.
Dunhill Financial left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1508 holding.
Dunhill Financial first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.